Procegence - ISPE Silver Corporate Partner

Image
2026-2027-Silver-Corporate-Partner-Graphic-Procegence

Website: https://www.procegence.com/

We’ve seen first-hand the cost of scale-up failures, tech transfer delays, and process inefficiencies. Procegence provides modeling and simulation services to solve these challenges across the full development lifecycle: process and product development, equipment selection and characterization, process optimization, and CMC.

Our consulting and model building services span in silico modeling, regulatory support, digitalization, risk assessment with changing process parameters, and device, facility, and equipment design. The output is actionable intelligence that can be applied to biopharma as well as adjacent industries like fine chemicals, food and beverage, and energy.

With on-demand services and fast turnaround, Procegence helps organizations reduce time, cost, and risk while improving yield, quality, and equipment performance.


Image
pharma-bioreactor-simualtion-750px.jpg

As your Simulation-as-a-Service partner, we provide high-fidelity mechanistic and hybrid modeling tailored to your specific process, equipment, and regulatory context.

We can support your work at every stage, from early process development through tech transfer, scaleup, and commercialization, bringing deep expertise in predictive modeling, digital twins, and CMC regulatory preparation.

Learn More        Follow US on Linkedin


What is Simulation-as-a-Service?

One of the biggest barriers to adoption of modeling & simulation is the concern about building infrastructure and expertise.

Simulation-as-a-Service is Procegence’s approach to providing customized, on-demand modeling & simulation, eliminating the need for companies to build that expertise in-house.

Learn More

Image
image-for-SaaS-ISPE-750px.jpg

Image
Siemens-case-study-750px.jpg

Case Study: When Physical DOE Isn’t an Option, Simulation Delivers.

What does a 12% improvement in product yield look like at biopharmaceutical scale? For one leading biopharma company running high-volume mAb bioprocessing, it translated to ~$20 million per year in additional revenue - without a single piece of new equipment. Working within the constraints of an existing brownfield GMP manufacturing setup, the Procegence team applied high-fidelity simulations to do what traditional DOE-based optimization simply couldn't, with three main outcomes:

  • A parameter space too complex for physical experimentation, solved. Simulation rapidly explored 147 scenarios across aeration rate, agitation speed, and impeller configuration, delivering optimization results that conventional methods couldn't feasibly reach.
  • A defined operating space with value beyond yield. Not only did the engagement improve the process, but it also produced a documented parameter space that the biopharma company can now use for process control, surrogate modeling, and regulatory communications.
  • Proof that simulation-driven development is a practical path, not a theoretical one. This is what in silico bioprocess optimization looks like at commercial scale: real constraints, real infrastructure, and measurable competitive advantage.

Learn More


Case Study: Spray Drying at Scale for Biologics

Image
Spray-Drying-Catelent-750px.jpg

Spray drying has been used for decades to solve one problem well: improving bioavailability for poorly soluble small molecules.

An executive summary featuring contributions from Procegence Founder, Nima Yazdanpanah, makes the case that, with GLP-1 agonists and oral peptide therapies pushing lyophilization capacity to its limits, spray drying is becoming a viable alternative.

Three realities are shaping what comes next: 

  • Scale-up is more complex than it looks. When moving from lab-scale to commercial-scale, spray drying behavior changes with regards to droplet formation, drying kinetics, and particle characteristics. Trial-and-error experimentation handles these dynamics poorly, which can cost millions with a single failed batch. 
  • Modeling & simulation close the gap. By predicting atomization behavior, droplet shrinkage, particle size distribution, and residual solvent content before lab work begins, mechanistic modeling eliminates the least viable development paths early, reserving physical runs for experiments most likely to succeed. 
  • The platform potential is real, but execution is everything. Spray drying is evolving to support peptides, biologics, and next-generation modalities at commercial scale. QbD principles and AI-driven tools are what translate that potential into a design space that holds up through tech transfer and regulatory review. 

Learn More


How Do We Do Work with Our Clients?

Every project begins with understanding a company’s goals and the specific business problems that are top of mind. From there, we define the scope, timeline, and cost. Our collaborative business workflow ensures alignment and transparency at every step:

Image
business-workflow.jpg

Reach out to learn more or to schedule a discovery call with our team.

Contact Us